Arcutis Biotherapeutics Highlights Promising Data for ZORYVE® at Fall Clinical Dermatology Conference
1. New Insights on Quality of Life Improvement for Atopic Dermatitis Patients
On October 24, 2025, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the presentation of significant new data regarding ZORYVE® (roflumilast) cream at the Fall Clinical Dermatology Conference held in Las Vegas from October 23 to 26, 2025. The findings emphasize ZORYVE's role in enhancing the quality of life for individuals suffering from atopic dermatitis, particularly in reducing sleep disruptions and providing long-term disease control for patients aged 2 years and older.
Clinical Findings on Sleep Disruption and Disease Control
Dr. Patrick Burnett, Chief Medical Officer at Arcutis Biotherapeutics, expressed enthusiasm about the new data, highlighting its importance in understanding the comprehensive benefits of ZORYVE cream. The presentations included one of the first analyses to address improvements in sleep disruption due to atopic dermatitis, showcasing how ZORYVE cream effectively alleviated this often-overlooked burden.
The data shared from three Phase 3 trials provided compelling evidence that ZORYVE cream 0.15% and 0.05% improved itch control and reduced the negative impact of atopic dermatitis on sleep among both children and adults. Specifically, patients aged 6 years and older and those aged 2 to 5 years demonstrated significant improvements in sleep quality when treated with ZORYVE compared to vehicle cream.
Key Statistics and Outcomes
Key results from the trials underscored the effectiveness of ZORYVE cream, with significant improvements in patient-reported outcomes:
- Sleep Impact Reduction: Participants reported a decrease in sleep loss and disturbance, with both age groups experiencing similar benefits.
- Itch Improvement: The daily Worst Itch Numeric Rating Scale (WI-NRS) showed greater improvement for ZORYVE cream users compared to those using vehicle cream, with statistically significant results (P<0.001 for older children and P<0.01 for younger children).
- Tolerability: ZORYVE was well tolerated, with treatment-related adverse events occurring in less than 6% of patients, and serious adverse events reported in less than 1%.
Mercedes E. Gonzalez, MD, a medical director at Pediatric Skin Research and lead author of the poster presentation, emphasized the importance of addressing sleep disruptions for families impacted by atopic dermatitis, stating, “ZORYVE offers a safe, nonsteroidal, and targeted treatment option. In addition, these results highlight the clinically meaningful benefit of ZORYVE cream on reducing itch and improving sleep in young children with atopic dermatitis.”
Long-Term Efficacy and Proactive Treatment
In addition to sleep-related outcomes, long-term data from the 52-week Phase 3 INTEGUMENT-OLE trial was presented, revealing that ZORYVE cream not only decreased signs and symptoms of atopic dermatitis but also maintained improvements over time.
Key findings from the INTEGUMENT-OLE trial included:
- Sustained Disease Control: The data indicated that participants who switched to a proactive twice-weekly application of ZORYVE after achieving clear skin maintained significant disease control for an extended period, with median durations of 238 days for young children and 281 days for older patients.
- Improvements in Skin Condition: At 56 weeks, more than half of the participants in both age groups achieved a validated Investigator Global Assessment score of ‘Clear’ or ‘Almost Clear’, showcasing the long-term efficacy of ZORYVE cream.
Recognition and Market Position
ZORYVE has established itself as a leading prescribed treatment for atopic dermatitis and other inflammatory skin conditions. The cream has garnered multiple accolades, including the prestigious "2025 Best of Beauty Breakthrough Award" from *Allure* and the National Psoriasis Foundation’s Seal of Recognition.
As the industry recognizes ZORYVE's clinical impact, Arcutis continues to position itself as a pioneer in dermatological innovation, with a commitment to addressing the pressing needs of patients dealing with immune-mediated dermatological diseases.
Conclusion
Arcutis Biotherapeutics' latest findings presented at the Fall Clinical Dermatology Conference reaffirm the company's dedication to advancing treatment options for atopic dermatitis. With ZORYVE cream's proven efficacy in improving quality of life and providing long-term control of atopic dermatitis, Arcutis is poised to make a significant impact in the field of dermatology, offering hope to patients and their families.
